These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 37603347)
1. Real-world experience with low-dose IL-2 for children and young adults with refractory chronic graft-versus-host disease. Wobma H; Kapadia M; Kim HT; Alvarez-Calderon F; Baumeister SHC; Duncan C; Forrest S; Gorfinkel L; Huang J; Lehmann LE; Li H; Schwartz M; Koreth J; Ritz J; Kean LS; Whangbo JS Blood Adv; 2023 Aug; 7(16):4647-4657. PubMed ID: 37603347 [TBL] [Abstract][Full Text] [Related]
2. Durability of clinical and immunologic responses to extended low-dose interleukin-2 therapy in patients with refractory chronic graft-versus-host disease. Donato V; Kim HT; Stowe P; Reynolds CG; Ritz J; Koreth J; Whangbo JS Front Immunol; 2022; 13():954966. PubMed ID: 36189229 [TBL] [Abstract][Full Text] [Related]
3. A phase 1 study of donor regulatory T-cell infusion plus low-dose interleukin-2 for steroid-refractory chronic graft-vs-host disease. Whangbo JS; Nikiforow S; Kim HT; Wahl J; Reynolds CG; Rai SC; Kim S; Burden A; Alho AC; Lacerda JF; Alyea EP; Cutler CS; Ho VT; Antin JH; Soiffer RJ; Ritz J; Koreth J Blood Adv; 2022 Nov; 6(21):5786-5796. PubMed ID: 35475885 [TBL] [Abstract][Full Text] [Related]
4. Dose-escalated interleukin-2 therapy for refractory chronic graft-versus-host disease in adults and children. Whangbo JS; Kim HT; Mirkovic N; Leonard L; Poryanda S; Silverstein S; Kim S; Reynolds CG; Rai SC; Verrill K; Lee MA; Margossian S; Duncan C; Lehmann L; Huang J; Nikiforow S; Alyea EP; Armand P; Cutler CS; Ho VT; Blazar BR; Antin JH; Soiffer RJ; Ritz J; Koreth J Blood Adv; 2019 Sep; 3(17):2550-2561. PubMed ID: 31471324 [TBL] [Abstract][Full Text] [Related]
5. Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease. Koreth J; Kim HT; Jones KT; Lange PB; Reynolds CG; Chammas MJ; Dusenbury K; Whangbo J; Nikiforow S; Alyea EP; Armand P; Cutler CS; Ho VT; Chen YB; Avigan D; Blazar BR; Antin JH; Ritz J; Soiffer RJ Blood; 2016 Jul; 128(1):130-7. PubMed ID: 27073224 [TBL] [Abstract][Full Text] [Related]
6. Efficiency and Toxicity of Ruxolitinib as a Salvage Treatment for Steroid-Refractory Chronic Graft-Versus-Host Disease. Wang D; Liu Y; Lai X; Chen J; Cheng Q; Ma X; Lin Z; Wu D; Xu Y Front Immunol; 2021; 12():673636. PubMed ID: 34276662 [TBL] [Abstract][Full Text] [Related]
8. A Prospective Study of Alemtuzumab as a Second-Line Agent for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell Transplantation. Khandelwal P; Emoto C; Fukuda T; Vinks AA; Neumeier L; Dandoy CE; El-Bietar J; Chandra S; Davies SM; Bleesing JJ; Jordan MB; Mehta PA; Jodele S; Grimley MS; Kumar A; Myers KC; Marsh RA Biol Blood Marrow Transplant; 2016 Dec; 22(12):2220-2225. PubMed ID: 27664325 [TBL] [Abstract][Full Text] [Related]
9. A high-dose pulse steroid regimen for controlling active chronic graft-versus-host disease. Akpek G; Lee SM; Anders V; Vogelsang GB Biol Blood Marrow Transplant; 2001; 7(9):495-502. PubMed ID: 11669216 [TBL] [Abstract][Full Text] [Related]
10. Extracorporeal photopheresis therapy in the management of steroid-refractory or steroid-dependent cutaneous chronic graft-versus-host disease after allogeneic stem cell transplantation: feasibility and results. Apisarnthanarax N; Donato M; Körbling M; Couriel D; Gajewski J; Giralt S; Khouri I; Hosing C; Champlin R; Duvic M; Anderlini P Bone Marrow Transplant; 2003 Mar; 31(6):459-65. PubMed ID: 12665841 [TBL] [Abstract][Full Text] [Related]
11. An Open-Label, Single-Arm, Multicenter Study of Ibrutinib in Japanese Patients With Steroid-dependent/Refractory Chronic Graft-Versus-Host Disease. Doki N; Toyosaki M; Shiratori S; Osumi T; Okada M; Kawakita T; Sawa M; Ishikawa T; Ueda Y; Yoshinari N; Nakahara S Transplant Cell Ther; 2021 Oct; 27(10):867.e1-867.e9. PubMed ID: 34102349 [TBL] [Abstract][Full Text] [Related]
12. Corticosteroid-Free Primary Treatment of Chronic Extensive Graft-versus-Host Disease Incorporating Rituximab. Solomon SR; Sizemore CA; Ridgeway M; Zhang X; Smith J; Brown S; Holland HK; Morris LE; Bashey A Biol Blood Marrow Transplant; 2015 Sep; 21(9):1576-82. PubMed ID: 25985915 [TBL] [Abstract][Full Text] [Related]
13. Interleukin-2 and regulatory T cells in graft-versus-host disease. Koreth J; Matsuoka K; Kim HT; McDonough SM; Bindra B; Alyea EP; Armand P; Cutler C; Ho VT; Treister NS; Bienfang DC; Prasad S; Tzachanis D; Joyce RM; Avigan DE; Antin JH; Ritz J; Soiffer RJ N Engl J Med; 2011 Dec; 365(22):2055-66. PubMed ID: 22129252 [TBL] [Abstract][Full Text] [Related]
14. The concurrent administration of imatinib with extracorporeal photopheresis leads to complete and durable responses in patients with refractory sclerotic type chronic graft-versus-host disease. Alsuliman T; Magro L; Coiteux V; Gauthier J; Srour M; Lionet A; Beauvais D; Yakoub-Agha I Curr Res Transl Med; 2020 Apr; 68(2):71-76. PubMed ID: 31631014 [TBL] [Abstract][Full Text] [Related]
15. A randomized phase 2 trial of pomalidomide in subjects failing prior therapy for chronic graft-versus-host disease. Curtis LM; Ostojic A; Venzon DJ; Holtzman NG; Pirsl F; Kuzmina ZJ; Baird K; Rose JJ; Cowen EW; Mays JW; Mitchell SA; Parsons-Wandell L; Joe GO; Comis LE; Berger A; Pusic I; Peer CJ; Figg WD; Cao L; Gale RP; Hakim FT; Pavletic SZ Blood; 2021 Feb; 137(7):896-907. PubMed ID: 32976576 [TBL] [Abstract][Full Text] [Related]
16. IL6-receptor antibody tocilizumab as salvage therapy in severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: a retrospective analysis. Kattner AS; Holler E; Holler B; Klobuch S; Weber D; Martinovic D; Edinger M; Herr W; Wolff D Ann Hematol; 2020 Apr; 99(4):847-853. PubMed ID: 32086584 [TBL] [Abstract][Full Text] [Related]
17. Phase I/IIa Study of Low Dose Subcutaneous Interleukin-2 (IL-2) for Treatment of Refractory Chronic Graft Versus Host Disease. Asano T; Matsuoka KI; Iyama S; Ohashi K; Inamoto Y; Ohwada C; Murata M; Satake A; Yoshida C; Nakase K; Mori Y; Tanimoto M Acta Med Okayama; 2016 Oct; 70(5):429-433. PubMed ID: 27777442 [TBL] [Abstract][Full Text] [Related]
18. Ibrutinib in Steroid-Refractory Chronic Graft-versus-Host Disease, a Single-Center Experience. Chin KK; Kim HT; Inyang EA; Ho V; Koreth J; Romee R; Gooptu M; Shapiro R; Antin J; Soiffer R; Jaglowski S; Pidala J; Cutler C Transplant Cell Ther; 2021 Dec; 27(12):990.e1-990.e7. PubMed ID: 34481113 [TBL] [Abstract][Full Text] [Related]
19. Efficiency and Toxicity of Imatinib Mesylate Combined with Atorvastatin Calcium in the Treatment of Steroid-Refractory Chronic Graft-versus-Host Disease: A Single-Center, Prospective, Single-Arm, Open-Label Study. Chen T; Li J; Wei X; Yao H; Zhu L; Liu J; Liu Y; Wang P; Feng Y; Gao S; Liu H; Wang L; Zhao L; Gao L; Zhang C; Gao L; Zhang X; Kong P Acta Haematol; 2024; 147(5):499-510. PubMed ID: 38232716 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of Ruxolitinib for Steroid-Refractory Chronic Graft-vs-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation. Wu H; Shi J; Luo Y; Tan Y; Zhang M; Lai X; Yu J; Liu L; Fu H; Huang H; Zhao Y JAMA Netw Open; 2021 Jan; 4(1):e2034750. PubMed ID: 33502484 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]